The reasoning behind this is that brain derived neurotrophic factor (BDNF) levels have been observed to fall in these patients. Given that PBI’s drug increases BDNF levels in brain tissue, it is hypothesized that this may be of benefit and increase the quality of life in cancer patients who receive radiation therapy. Phoenix Biotechnology is delighted that NIH has recognized the value of our drug for this purpose and will work closely with them in these ongoing studies.